FOLH1 and metastatic prostate carcinoma: Following promising preclinical results with radiolabeled PSMA-617 developed at the German Cancer Research Center in Heidelberg, Germany [14], 177Lu-PSMA-617 was successfully used on a compassionate basis in patients with metastatic prostate cancer treated at German centres [16,17,18,19,20,21].